Termine
Präsentationen
Aktie
Aktueller Finanzbericht
News
Neueste
Tweets
vor 2 Wochen 5 Tage
@MorphoSys
Today´s Capital Markets Day live from NY at 10am EST, follow us over webcast https://t.co/hRycQXYxCs $MPSYF
vor 2 Wochen 6 Tage
@MorphoSys
London calling – join our Capital Markets Day at 9:30am BST live via webcast https://t.co/hRycQXYxCs $MPSYF
vor 3 Wochen 4 Stunden
@MorphoSys
Find out about MorphoSys future growth drivers at our Capital Markets Days in London and NY https://t.co/hRycQXYxCs $MPSYF
vor 1 Monat 3 Wochen
@MorphoSys
Proprietary blood cancer program MOR208 enters phase 3 clinical trial https://t.co/jKcqkEyhcU $MPSYF
vor 1 Monat 3 Wochen
@MorphoSys
MorphoSys with Significant Progress in its Therapeutic Programs inQ2 2017 https://t.co/5zZdvqZT35 $MPSYF
vor 2 Monate 1 Woche
@MorphoSys
MorphoSys first antibody based on proprietary technology with US FDA
approval. More about Tremfya(TM) https://t.co/XeVwH0SfCm $MPSYF
vor 2 Monate 1 Woche
@MorphoSys
MorphoSys Licensee Janssen Has Received US FDA Approval for Tremfya(TM) (Guselkumab) https://t.co/gL4CdndtyR $MPSYF
vor 3 Monate 3 Wochen
@MorphoSys
MorphoSys starts Phase 3 Trial of MOR208 plus bendamustine vs. rituximab plus bendamustine in R/R DLBCL https://t.co/5RxNdrgxOn $MPSYF
vor 4 Monate 1 Woche
@MorphoSys
MorphoSys announces positive 1st results from phase 1 study with lanthipeptide MOR107 in healthy volunteers https://t.co/69X6HDWU9d $MPSYF
vor 4 Monate 3 Wochen
@MorphoSys
MorphoSys reports solid first quarter 2017 with further progress in proprietary and
partnered pipeline https://t.co/RpAlVytntf $MPSYF
Medien und Investoren
Anke Linnartz
Vice President, Head of Corporate Communications and IR
Telefon +49 89 89927 404
Fax: +49 89 89927 5404
Alexandra Goller
Senior Manager Corporate Communications and Investor Relations
Telefon +49 89 89927 404
Fax: +49 89 89927 5404
Jochen Orlowski
Associate Director Corporate Communications and Investor Relations
Telefon +49 89 89927 404
Fax: +49 89 89927 5404